1. Home
  2. TY vs XOMAP Comparison

TY vs XOMAP Comparison

Compare TY & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TY
  • XOMAP
  • Stock Information
  • Founded
  • TY 1929
  • XOMAP N/A
  • Country
  • TY United States
  • XOMAP United States
  • Employees
  • TY N/A
  • XOMAP 13
  • Industry
  • TY Finance Companies
  • XOMAP Biotechnology: Pharmaceutical Preparations
  • Sector
  • TY Finance
  • XOMAP Health Care
  • Exchange
  • TY Nasdaq
  • XOMAP Nasdaq
  • Market Cap
  • TY N/A
  • XOMAP N/A
  • IPO Year
  • TY N/A
  • XOMAP N/A
  • Fundamental
  • Price
  • TY $31.35
  • XOMAP $25.87
  • Analyst Decision
  • TY
  • XOMAP
  • Analyst Count
  • TY 0
  • XOMAP 0
  • Target Price
  • TY N/A
  • XOMAP N/A
  • AVG Volume (30 Days)
  • TY 43.0K
  • XOMAP N/A
  • Earning Date
  • TY 01-01-0001
  • XOMAP N/A
  • Dividend Yield
  • TY 3.36%
  • XOMAP N/A
  • EPS Growth
  • TY N/A
  • XOMAP N/A
  • EPS
  • TY 4.78
  • XOMAP N/A
  • Revenue
  • TY N/A
  • XOMAP N/A
  • Revenue This Year
  • TY N/A
  • XOMAP N/A
  • Revenue Next Year
  • TY N/A
  • XOMAP N/A
  • P/E Ratio
  • TY $6.38
  • XOMAP N/A
  • Revenue Growth
  • TY N/A
  • XOMAP N/A
  • 52 Week Low
  • TY $25.16
  • XOMAP N/A
  • 52 Week High
  • TY $30.73
  • XOMAP N/A
  • Technical
  • Relative Strength Index (RSI)
  • TY 24.47
  • XOMAP 51.26
  • Support Level
  • TY $31.83
  • XOMAP $25.52
  • Resistance Level
  • TY $32.23
  • XOMAP $25.92
  • Average True Range (ATR)
  • TY 0.35
  • XOMAP 0.15
  • MACD
  • TY -0.34
  • XOMAP 0.00
  • Stochastic Oscillator
  • TY 4.89
  • XOMAP 87.23

About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Share on Social Networks: